Sponsor: Puma Biotechnology, Inc.
Sponsor Study ID: PUMA-ALI-4201
Study Title: A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
CTO #: 104013
NCT Number: NCT06095505
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lung
Study Objectives: Determine whether any biomarker correlates with alisertib response. Determine investigator-assessed efficacy in the patient population. Determine survival outcomes in the patient population. Determine the safety profile of alisertib. Update the population pharmacokinetic (popPK) profile of alisertib